Literature DB >> 20553377

The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation.

L Jungbauer, C Dobias, C Stöllberger, F Weidinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20553377     DOI： 10.1111/j.1538-7836.2010.03943.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  14 in total

1.  Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  J Neurol       Date:  2011-11-29       Impact factor: 4.849

2.  The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.

Authors:  Dorien Groenendaal; Gregory Strabach; Alberto Garcia-Hernandez; Takeshi Kadokura; Marten Heeringa; Roelof Mol; Charlotte Eltink; Hartmut Onkels
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 3.  Pharmacology of the new target-specific oral anticoagulants.

Authors:  Katherine P Cabral
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

Review 4.  Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly.

Authors:  Virginie Siguret; Isabelle Gouin-Thibault; Pascale Gaussem; Eric Pautas
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

Review 5.  Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.

Authors:  C Stöllberger; J Finsterer
Journal:  Herz       Date:  2015-01-25       Impact factor: 1.443

6.  Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.

Authors:  Meyer Michel Samama; Céline Guinet; Léna Le Flem; Emmanuel Ninin; Jean-Marc Debue
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 7.  Dabigatran and kidney disease: a bad combination.

Authors:  Felix Knauf; C Michael Chaknos; Jeffrey S Berns; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

8.  In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.

Authors:  Sophie Hodin; Thierry Basset; Elodie Jacqueroux; Olivier Delezay; Anthony Clotagatide; Nathalie Perek; Patrick Mismetti; Xavier Delavenne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

9.  Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.

Authors:  David Faraoni; Jerrold H Levy; Pierre Albaladejo; Charles-Marc Samama
Journal:  Crit Care       Date:  2015-04-29       Impact factor: 9.097

10.  Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.